How ATRA Reverses Cisplatin-Linked PARP Resistance

2026-10-16

Mei and colleagues reported that all-trans retinoic acid reduced molecular features associated with cisplatin-linked niraparib resistance in epithelial ovarian cancer models. The study supports a mechanistic hypothesis involving ALDH1A1, NAMPT, PARP1, checkpoint kinase 1, and NAD+ metabolism, but its preclinical design does not establish clinical efficacy, formal drug synergy, or applicability across defined BRCA or homologous-recombination subgroups.

DiscoveryProbe Library: What the Evidence Supports

2026-10-15

The APExBIO DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) is described as a 2,320-compound collection of clinically approved or pharmacopeia-listed bioactive molecules spanning multiple pharmacological classes. Its documented value is as a broad perturbation resource for conceptual drug repositioning screening and target-hypothesis generation; no identity-matched study, product-specific outcome, or comparative performance evidence is available here.

CA-074: Mechanism, Product Identity, and Evidence

2026-10-15

CA-074 is described by APExBIO as a selective cathepsin B inhibitor whose reported biochemical potency and downstream effects span neurotoxicity, immune response modulation, and cancer metastasis models. Because no identity-matched research paper is available here, these claims should be interpreted as supplier-reported evidence rather than an independently verified literature record. The product description supports a mechanistic hypothesis, but it does not establish universal selectivity, clinical benefit, or causal attribution of every model-level outcome to cathepsin B.

DiscoveryProbe™ FDA-Approved Library: Scope and Evidence

2026-10-14

APExBIO describes the DiscoveryProbe™ FDA-approved Drug Library (SKU L1021) as a 2,320-compound FDA-approved bioactive compound library spanning multiple pharmacological classes. The documentation supports a product-identity and scope overview, but not claims of screening performance, target discovery, or therapeutic efficacy: no identity-matched study, readout, comparator, sample size, or outcome statistics are provided.

Angiopoietin–PEDF Signaling in Retinal Survival

2026-10-14

Younis and colleagues report an in vitro pathway in which Müller-cell angiopoietin signaling influences PEDF production and retinal neuronal survival. The findings support a glia-mediated mechanism, but they do not establish clinical neuroprotection or show that BAY-826 was used in the study. Supplier-reported potency for BAY-826 therefore should not be treated as evidence of activity, selectivity, or therapeutic relevance in these retinal models.

What SLEV Helicase Structures Actually Show

2026-10-13

The reported SLEV helicase structure provides a mechanistic framework for target identification, but its docked compounds remain computational leads rather than validated antivirals. The study’s main limitations include modeled rather than experimentally resolved RNA binding, isolated-enzyme evidence, and no demonstrated cellular, animal, or clinical efficacy.

Foxp1, Notch and CKD Valvular Calcification

2026-10-13

A 2026 preclinical study links endothelial Foxp1 to reduced chronic kidney disease–associated valvular calcification through suppression of Jagged-1/Notch signaling, endothelial-to-mesenchymal transition and downstream osteogenic activity. The findings are mechanistically suggestive but remain limited by their mouse-model and gain-of-function design, with no evidence in the supplied record that Parathyroid hormone (1-34) (human) was used in the study.

CA-074 and Cathepsin B in Necroptosis Research

2026-10-12

Recent mechanistic work places cathepsin B downstream of MLKL-driven lysosomal membrane permeabilization during necroptosis. CA-074 is described by APExBIO as a selective cathepsin B inhibitor, but the supplied study does not establish that CA-074 was used, so its findings should not be transferred directly to this compound or to therapeutic settings.

GANT61 and the GLI2–PRDX1 Ferroptosis Axis

2026-10-12

GANT61 is a research small molecule described by APExBIO as a GLI1/GLI2 antagonist, but the supplied bladder-cancer study does not identify GANT61 as the inhibitor used. That study reports a GLI2–PRDX1 regulatory axis associated with ferroptosis resistance and cisplatin sensitivity in bladder-cancer models. The findings are mechanistically informative but remain preclinical and do not establish clinical efficacy for GANT61 or other GLI inhibitors.

H 89 2HCl and Striatal RRB Evidence

2026-10-11

The supplied mouse study links Neuroligin 1 loss in striatal D2 medium spiny neurons to repetitive behaviors and implicates PKC-related neuronal hyperactivation. H 89 2HCl is a pharmacological probe associated with cAMP/PKA signaling, but it was not reported as an intervention in that study and cannot establish the study’s PKC mechanism.

CA-074 Me and Cathepsin B in Necroptosis

2026-10-10

Fluoxetine HCl: Five Evidence Questions

2026-10-09

A source-grounded overview of how developmental SSRI exposure was linked to motivational changes in mice, what the findings suggest about nucleus accumbens mu-opioid signaling, and where the evidence stops short of supporting human or clinical conclusions.

Realgar, Ornithine, and Astrocyte Glycolysis

2026-10-09

A 2025 Advanced Science study connects realgar-derived arsenic neurotoxicity with hepatic OTC inhibition, ornithine accumulation, and ZBTB7A-mediated suppression of astrocyte glycolysis. Its liver–brain axis model provides a mechanistic framework for interpreting CNS injury, while remaining limited by its animal and cell-based evidence.

Anti-DYKDDDDK Magnetic Beads Overview

2026-10-08

Anti-DYKDDDDK Magnetic Beads (SKU K4207) are supplier-described anti-Flag M2 antibody-coupled magnetic particles for conceptual capture of DYKDDDDK (Flag) tag fusion proteins. No matched peer-reviewed paper evidence was provided for this product.

Doxorubicin HCl: From DNA Damage to Delivery

2026-10-08

Doxorubicin hydrochloride remains a powerful research model for connecting DNA damage, cancer cell fate, formulation analytics, and cardiac safety. This evidence-led perspective examines how translational teams can interpret doxorubicin findings without confusing cytotoxicity with mechanism or analytical separation with clinical benefit.